Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany) - Hallo friendsTOP POLENNEWS, In the article you read this time with the title Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany), We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany)
link : Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany)

Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany)

A prior trial tested this vaccine (IDH1 R132H peptide vaccine) for gliomas with this IDH1 mutation.  The current trial is testing vaccine alone versus avelumab (PD-L1 inhibitor) alone versus combined vaccine + avelumab.

It is recruiting first recurrent gliomas of grade 2-4 with the IDH1 R132H mutation.

Open in Heidelberg and Mannheim Germany, and will also be open at several other centres in Germany.

https://clinicaltrials.gov/ct2/show/NCT03893903

Thus Article Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany)

That's an article Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany) This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Clinical trial: IDH1 R132H peptide vaccine + avelumab (Germany) with the link address https://polennews.blogspot.com/2019/04/clinical-trial-idh1-r132h-peptide.html

Tweet

Subscribe to receive free email updates: